Spruce Biosciences Yönetim

Yönetim kriter kontrolleri 3/4

Spruce Biosciences CEO'su Javier Szwarcberg, Jan2022 tarihinde atandı, in görev süresi 2.83 yıldır. in toplam yıllık tazminatı $ 2.16M olup, şirket hissesi ve opsiyonları dahil olmak üzere 26.9% maaş ve 73.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.26% ine doğrudan sahiptir ve bu hisseler $ 52.59K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 4.8 yıldır.

Anahtar bilgiler

Javier Szwarcberg

İcra Kurulu Başkanı

US$2.2m

Toplam tazminat

CEO maaş yüzdesi	26.9%
CEO görev süresi	2.8yrs
CEO sahipliği	0.3%
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	4.8yrs

Son yönetim güncellemeleri

Recent updates

Insufficient Growth At Spruce Biosciences, Inc. (NASDAQ:SPRB) Hampers Share Price

May 29

Is Spruce Biosciences, Inc. (NASDAQ:SPRB) Popular Amongst Institutions?

Jan 12

Spruce Biosciences outlines milestones for 2021

Jan 06

CEO Tazminat Analizi

Javier Szwarcberg'un ücretlendirmesi Spruce Biosciences'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$39m
Jun 30 2024	n/a	n/a	-US$43m
Mar 31 2024	n/a	n/a	-US$47m
Dec 31 2023	US$2m	US$580k	-US$48m
Sep 30 2023	n/a	n/a	-US$49m
Jun 30 2023	n/a	n/a	-US$48m
Mar 31 2023	n/a	n/a	-US$47m
Dec 31 2022	US$4m	US$540k	-US$46m

Tazminat ve Piyasa: Javier 'nin toplam tazminatı ($USD 2.16M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 652.28K ).

Tazminat ve Kazançlar: Javier 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Javier Szwarcberg (54 yo)

2.8yrs

Görev süresi

US$2,157,418

Tazminat

Dr. Javier Szwarcberg, M.D., M.P.H., is CEO & Director of Spruce Biosciences, Inc. from January 2022. Dr. Szwarcberg is an accomplished physician executive with many years of leadership experience in the b...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Grey	Executive Chairman	7.6yrs	US$119.39k	0% $ 0
Javier Szwarcberg	CEO & Director	2.8yrs	US$2.16m	0.26% $ 52.6k
Samir Gharib	President & CFO	4.5yrs	US$1.20m	0.49% $ 99.4k
Ralph Charlton	Chief Medical Officer	2.7yrs	US$1.00m	0.13% $ 27.1k
P. Ramtin	Senior Vice President of Business Operations	2.3yrs	Veri yok	Veri yok
Heidi Petersen	Senior Vice President of Regulatory & Quality	1.3yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: SPRB 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Grey	Executive Chairman	7.6yrs	US$119.39k	0% $ 0
Javier Szwarcberg	CEO & Director	2.8yrs	US$2.16m	0.26% $ 52.6k
Daniel Spiegelman	Independent Director	4.2yrs	US$106.89k	0% $ 0
Tiba Aynechi	Independent Director	8.5yrs	US$99.39k	0% $ 0
Percival Barretto-Ko	Independent Director	1.5yrs	US$127.84k	0% $ 0
Balaji Muralidhar	Independent Director	4.8yrs	US$94.39k	0% $ 0
Camilla Simpson	Independent Director	7.1yrs	US$98.39k	0% $ 0

4.8yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SPRB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.8 yıldır).

Spruce Biosciences Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Spruce Biosciences, Inc., Annual General Meeting, May 22, 2024

CEO & Director exercised options and sold US$64k worth of stock

President & CFO exercised options and sold US$56k worth of stock

Spruce Biosciences, Inc. Appoints Percival Barretto-Ko to Board of Directors

High number of new directors

Spruce Biosciences, Inc. Appoints P. J. Ramtin as Senior Vice President of Business Operations

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Nasdaq Grants Spruce Biosciences an Additional 180 Calendar Days, or Until April 21, 2025, to Regain Compliance with the Minimum Closing Bid Price Requirement

Consensus EPS estimates upgraded to US$1.04 loss

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Spruce Biosciences, Inc. (NasdaqGS:SPRB) completed the acquisition of Substantially all of rights, title, interests, assets in Avexitide of Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $10 million.

New major risk - Revenue and earnings growth

Spruce Biosciences, Inc. Presents Phase 2 POWER Study Results of Tildacerfont for Treatment of Polycystic Ovary Syndrome at ENDO 2024

Insufficient Growth At Spruce Biosciences, Inc. (NASDAQ:SPRB) Hampers Share Price

Spruce Biosciences, Inc. Receives Non-Compliance Notice Regarding Nasdaq's Listing Rule 5450(a)(1)

Spruce Biosciences, Inc., Annual General Meeting, May 22, 2024

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target decreased by 26% to US$6.17

Spruce Biosciences, Inc. Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH

Spruce Biosciences, Inc. Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia

Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH

CEO & Director exercised options and sold US$64k worth of stock

Consensus revenue estimates increase by 16%, EPS downgraded

New minor risk - Share price stability

Spruce Biosciences, Inc. Completes Target Enrollment of CAHmelia-203 Study in Adult Classic Congenital Adrenal Hyperplasia

Price target increased by 13% to US$8.50

Consensus revenue estimates increase by 51%

President & CFO exercised options and sold US$56k worth of stock

Consensus revenue estimates increase by 23%

Spruce Biosciences, Inc. Appoints Percival Barretto-Ko to Board of Directors

Consensus revenue estimates fall by 56%

Price target decreased by 18% to US$7.00

Consensus revenue estimates increase by 17%

Spruce Biosciences, Inc. announced that it expects to receive $51.08772 million in funding from a group of investors

Spruce Biosciences Provides Clinical Program Updates

Price target decreased to US$8.29

High number of new directors

Spruce Biosciences, Inc. Appoints P. J. Ramtin as Senior Vice President of Business Operations

Price target increased to US$10.40

Spruce Biosciences, Inc.(NasdaqGS:SPRB) dropped from Russell 2500 Index

High number of new directors

Spruce Biosciences, Inc. Appoints Libbie Mansell as Chief Regulatory and Quality Officer

Spruce Biosciences, Inc., Annual General Meeting, May 25, 2022

Price target decreased to US$9.83

High number of new directors

Price target decreased to US$17.60

Spruce Biosciences, Inc. Announces Details of its Phase 2 Clinical Program for Tildacerfont in Pediatric Classic CAH During its Virtual Research and Development Day

High number of new directors

Spruce Biosciences, Inc.(NasdaqGS:SPRB) dropped from Russell Microcap Growth Index

Spruce Biosciences, Inc. Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism

Independent Director has left the company

Spruce Biosciences, Inc. Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at 23rd European Congress of Endocrinology

Independent Director notifies of intention to sell stock

Spruce Biosciences, Inc. to Announces Phase 1 and 2 Data of Tildacerfont At Endocrine Society’S 2021 Annual Meeting

Jonas Hansson, Member of the Board of Directors and a Member of the Audit Committee of Spruce Biosciences, Inc. Not Intend to Stand for Reelection at the Company's 2021 Annual Meeting of Stockholders

New 90-day low: US$20.01

Is Spruce Biosciences, Inc. (NASDAQ:SPRB) Popular Amongst Institutions?

Spruce Biosciences outlines milestones for 2021

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş